Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ME 1111

Drug Profile

ME 1111

Alternative Names: ME-1111

Latest Information Update: 14 Mar 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Meiji Seika Pharma
  • Class Antifungals
  • Mechanism of Action Succinate cytochrome c oxidoreductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Onychomycosis

Most Recent Events

  • 01 Feb 2018 Phase-II clinical trials in Onychomycosis in Japan (Topical) (JapicCTI183840)
  • 01 Feb 2018 Meiji Seika Pharma plans a phase II trial for Onychomycosis in Japan (JapicCTI183840)
  • 18 Apr 2016 ME 1111 is still in phase II trials for Onychomycosis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top